<unk>  affects approximately a third of patients with type 1 and type 2 diabetes mellitus.<unk>  is responsible for about a third of cases of ESRD worldwide, and an even larger fraction in the developed countries. Worldwide, the prevalence of diabetes is projected to increase from 382 million in 2013, to over 592 million by 2035. This increase is projected to be sharpest in developed countries. The prevalence of type 2 DM is particularly increasing due to the rising prevalence of obesity worldwide.<unk>  kidney disease progression could lead to ESRD as well as an increased risk of cardiovascular complications, all of which cause a substantial economic burden. The estimated cost of management of patients with ESRD due to<unk>  in the US is 39.35 billion USD in 2010. Within developed countries, certain ethnic groups such as African Americans and Native Americans are at higher risk of developing<unk>  and ESRD.
Diabetic nephropathy
Analgesic nephropathy
IgA nephropathy
Benign nephrosclerosis
Malarial nephropathy
Phosphate nephropathy
Reflux nephropathy
Sickle cell nephropathy